New hope for rare heart disease: drug trial shows promise in japanese patients

NCT ID NCT04622046

First seen Jan 10, 2026 · Last updated Apr 26, 2026 · Updated 16 times

Summary

This study tested a drug called ALXN2060 in 25 Japanese adults with a rare heart condition called ATTR-CM, which causes heart failure. The goal was to see if the drug helps patients walk farther, reduces hospital stays, and improves survival over 30 months. All participants received the drug alongside their usual heart failure treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYMPTOMATIC TRANSTHYRETIN AMYLOID CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Bunkyō City, 113-8431, Japan

  • Research Site

    Fukuoka, 812-8582, Japan

  • Research Site

    Kumamoto, 860-8556, Japan

  • Research Site

    Kurume-shi, 830-0011, Japan

  • Research Site

    Matsumoto-shi, 390-8621, Japan

  • Research Site

    Nagoya, 466-8560, Japan

  • Research Site

    Nankoku-shi, 783-8505, Japan

  • Research Site

    Sagamihara-shi, 252-0375, Japan

  • Research Site

    Sapporo, 060-8543, Japan

  • Research Site

    Shinjuku-ku, 160-8582, Japan

  • Research Site

    Suita-shi, 564-8565, Japan

Conditions

Explore the condition pages connected to this study.